CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the clinical launch of its ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced results from a new study demonstrating that its algorithmic test, Immune ...

Tempus AI Inc. TEM shares are up on Thursday as Mizuho initiated coverage on the health care-focused artificial intelligence ...

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of the ...

Tempus AI stock is showing a mixed technical picture, with a moderately bearish trend and ongoing selling pressure, indicating potential downside risk. The stock, at $69.85, sits well below its ...

Tempus AI TEM rose on Wednesday after the company unveiled its new HRD-RNA algorithm, an AI-driven tool designed to improve detection of homologous recombination deficiency (HRD) in tumors. The ...

Tempus AI (TEM) announced the clinical launch of its Immune Profile Score (IPS) algorithmic test. IPS, which is now available for clinicians to order, is a multimodal biomarker that can be used as a ...

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Ambry Genetics, part of Tempus AI, contributed to research using advanced genetic ...

Tempus AI has expanded its relationship with Personalis, investing $36 million in the oncology biotech and becoming the exclusive commercial partner for its test to detect minimal residual disease, or ...